Your browser doesn't support javascript.
loading
Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
Bello, Ezia; Brich, Silvia; Craparotta, Ilaria; Mannarino, Laura; Ballabio, Sara; Gatta, Raffaella; Marchini, Sergio; Carrassa, Laura; Matteo, Cristina; Sanfilippo, Roberta; Gronchi, Alessandro; Casali, Paolo Giovanni; Pilotti, Silvana; D'Incalci, Maurizio; Frapolli, Roberta.
Afiliación
  • Bello E; Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156, Milan, Italy.
  • Brich S; Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133, Milan, Italy.
  • Craparotta I; Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156, Milan, Italy.
  • Mannarino L; Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156, Milan, Italy.
  • Ballabio S; Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156, Milan, Italy.
  • Gatta R; Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156, Milan, Italy.
  • Marchini S; Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156, Milan, Italy.
  • Carrassa L; Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156, Milan, Italy.
  • Matteo C; Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156, Milan, Italy.
  • Sanfilippo R; Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133, Milan, Italy.
  • Gronchi A; Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133, Milan, Italy.
  • Casali PG; Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133, Milan, Italy.
  • Pilotti S; Laboratory of Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133, Milan, Italy.
  • D'Incalci M; Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156, Milan, Italy. maurizio.dincalci@marionegri.it.
  • Frapolli R; Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156, Milan, Italy.
Br J Cancer ; 122(7): 1120, 2020 Mar.
Article en En | MEDLINE | ID: mdl-32047297
ABSTRACT
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Br J Cancer Año: 2020 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Br J Cancer Año: 2020 Tipo del documento: Article País de afiliación: Italia